Tetsuya Nishimura
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Journal: Pharmacology research & perspectives
Published: December 04, 2020
Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Journal: British journal of clinical pharmacology
Published: June 29, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Journal: Clinical drug investigation
Published: April 11, 2020
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: February 19, 2020
A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Journal: European journal of clinical pharmacology
Published: January 13, 2020
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Journal: Clinical drug investigation
Published: November 16, 2019
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Journal: Clinical pharmacology in drug development
Published: August 20, 2019
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Journal: Clinical pharmacokinetics
Published: November 24, 2016
Fever of unknown origin successfully treated by oren-gedoku-to (huanglian-jie-du-tang).
Journal: International journal of general medicine
Published: October 15, 2013
Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
Journal: Investigational new drugs
Published: June 29, 2012
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.
Journal: Cancer chemotherapy and pharmacology
Published: February 28, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026